BianchiSchwald has successfully assisted Sparta Capital Management Ltd in providing EUR 21.5 million in debt and equity financing to HYGH. The funding will fuel HYGH’s expansion in the German market, propelling the fast-growing digital advertising
Tags :dx3
Niederer Kraft Frey has promoted Aurélien Charmillot to senior associate, effective 1 July 2023. With this appointment the firm recognises the great work of the lawyer based in Geneva. Charmillot’s practice focuses on dispute resolution
Walder Wyss is acting as legal counsel to Tradeplus24 (TP24), a Zurich-based FinTech SME lender, on its successful completion of a significant debt financing round, raising CHF 400 million. The funding was secured through a CHF 355
Niederer Kraft Frey advised Oliver Healthcare Packaging, a renowned supplier of sterile barrier flexible packaging solutions for the global healthcare market, as Swiss local counsel on the successful acquisition of EK-Pack Folien and its Swiss
Wenger Vieli has advised Swiss FinTech company, Numarics on all legal matters related to its seed financing round. Numarics, a company specializing in mobile-driven finance and business management solutions, aims to revolutionize the way entrepreneurs
Wenger Vieli acted as the legal advisor to the sellers of Seervision, a Swiss company specializing in AI-driven camera automation solutions, in its acquisition by QSC. The partnership marks a significant milestone for Seervision, opening
Nadine Grüter has joined Wenger Vieli from the District Court of Baden, where she was a law clerk. Grüter advises and represents national and international companies and private individuals in construction and real
Homburger has provided legal counsel to Santhera Pharmaceuticals Holding (SIX: SANN “Santhera”) on its completion of a 10:1 reverse split of its shares. The reverse split, which was approved by shareholders on June 27, 2023, resulted in the
RELIEF THERAPEUTICS Holding has entered into has entered into a definitive agreement for the sale and purchase in a private placement of 1.5m Relief shares and warrants to purchase up to 1.5m Relief shares. The
Oculis Holding, a global biopharmaceutical company purposefully driven to save sight and improve eye care, has placed a follow-on public offering of 3.5m ordinary shares at a public offering price of USD 11.50 per ordinary share,
